Bioventix Plc Notice of AGM

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or the "Company") 
 
                  Notice of AGM and Posting of Annual Report 
 
Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will be 
held at The Winchester Suite, Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 
p.m. on Wednesday 7 December 2016. 
 
Copies of the 2016 Annual Report and the Notice of the Annual General Meeting 
have been sent to shareholders and are also available on the Company's website 
at www.bioventix.com. 
 
For further information please contact: 
 
Bioventix plc                                             Tel: 01252 728 001 
Peter Harrison               Chief Executive Officer 
 
finnCap Ltd                                               Tel: 020 7220 0500 
Geoff Nash/Simon Hicks       Corporate Finance 
Steve Norcross               Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END

(END) Dow Jones Newswires

November 14, 2016 06:47 ET (11:47 GMT)

Bioventix (LSE:BVXP)
Historical Stock Chart
From Apr 2024 to May 2024